Cover Image

Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

A phase I, open‐label study (NCT02197234) assessed the effects of osimertinib on simvastatin exposure in patients with advanced epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer and disease progression post‐EGFR tyrosine kinase inhibitor treatment. Here, we report on a retro...

Full description

Saved in:

Bibliographic Details
Main Authors:	Karthick Vishwanathan (Author), Mireille Cantarini (Author), Karen So (Author), Eric Masson (Author), Jennifer Fetterolf (Author), Suresh S. Ramalingam (Author), R. Donald Harvey (Author)
Format:	Book
Published:	Wiley, 2020-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
by: Thomas Rodier, et al.
Published: (2022)

CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
by: Teerapat Majam, et al.
Published: (2023)

Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
by: Simon Ekman, et al.
Published: (2023)

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
by: Yan Hu, et al.
Published: (2022)

Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer
by: Apoorva Daram, et al.
Published: (2024)

Drug-induced subacute cutaneous lupus erythematosus involving osimertinib
by: Christian L. Bailey-Burke, AB, et al.
Published: (2024)

Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report
by: Wang Shujun, et al.
Published: (2022)

Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand
by: Thananan Rattanachotphanit, et al.
Published: (2019)

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment
by: Karthick Vishwanathan, et al.
Published: (2020)

Subacute cutaneous lupus erythematosus following osimertinib therapy for non-small cell lung cancer: A case report
by: Eun Jae Kim, BA, et al.
Published: (2024)

In vitro permeation and stability studies on developed drug-in-adhesive transdermal patch of simvastatin
by: Rabinarayan Parhi, et al.
Published: (2018)

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Gengwei Huo, et al.
Published: (2024)

A Drug–Drug Interaction Study to Evaluate the Impact of Simvastatin and Itraconazole on Erlotinib Pharmacokinetics in Rats by UPLC-MS/MS
by: Fan Z, et al.
Published: (2023)

Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer
by: Yongkuan Guo, et al.
Published: (2024)

miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44
by: Shang-Gin Wu, et al.
Published: (2024)

Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
by: Diansong Zhou, et al.
Published: (2019)

Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction
by: Luna Prieto Garcia, et al.
Published: (2022)

Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer
by: Hang Li, et al.
Published: (2022)

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation-Positive Lung Cancer Cells
by: Paulina Skupin-Mrugalska, et al.
Published: (2020)

Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction
by: Methira Siriangkhawut, et al.
Published: (2017)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
by: Haifeng Qin, et al.
Published: (2021)

Bioaccumulation and biotransformation of simvastatin in probiotic bacteria: A step towards better understanding of drug-bile acids-microbiome interactions
by: Maja Đanić, et al.
Published: (2023)

Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report
by: Jowan Al-Nusair MD, et al.
Published: (2024)

Osimertinib-associated ashy dermatosis-like hyperpigmentation
by: Pattamon Lertpichitkul, MD, et al.
Published: (2020)

Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt/β-catenin pathway
by: Shuliu Sang, et al.
Published: (2022)

Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
by: Jingjing Shi, et al.
Published: (2023)

Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and Gardenia jasminoides J. Ellis
by: Ziwei Li, et al.
Published: (2021)

Prevalence and clinical significance of potential drug-drug interactions among lung transplant patients
by: Jiali Zhang, et al.
Published: (2024)

Corrigendum to "Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis" [Pharmacol. Res. 188 (2023) 106668]
by: Tianyao Lei, et al.
Published: (2023)

Development and Evaluation of Self-Emulsifying Drug-Delivery System–Based Tablets for Simvastatin, a BCS Class II Drug
by: Bashir MA, et al.
Published: (2023)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
by: Caterina Gianni, et al.
Published: (2021)

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review
by: Xiaofei Gu, et al.
Published: (2024)

Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in Patients With Hyperlipidemia
by: Yu-An Chen, et al.
Published: (2018)

Pharmacoeconomic evaluation of drug supply for chemotherapy in small cell lung cancer
by: Yelena A. Lunyova
Published: (2023)

Pharmacokinetic Drug-Drug Interactions and Herb-Drug Interactions
by: Min-Koo Choi, et al.
Published: (2021)

Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study
by: Zheng Yuan, et al.
Published: (2022)

Tannic Acid-Lung Fluid Assemblies Promote Interaction and Delivery of Drugs to Lung Cancer Cells
by: Elham Hatami, et al.
Published: (2018)

Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
by: Thiviyadarshini Rajasegaran, et al.
Published: (2023)